GlassScriptPhysician profile
Jacob Wolfe
NPI 1891475943
$1,297.73
in general payments reported to CMS, 2019-2025
31 companies · $785 in 2025
The $785 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $513 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960 · Travel and Lodging: $238 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.87 |
| Travel and Lodging | $237.86 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $354.85 | 2024 | |
| Conmed Corporation | $114.88 | 2025 | Airseal |
| Sobi, INC | $78.60 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $62.42 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $58.78 | 2024-2025 | Dupixent, Libtayo |
| Daiichi Sankyo INC. | $46.10 | 2025 | Enhertu, Datroway |
| Aveo Pharmaceuticals, INC. | $41.10 | 2025 | |
| Spectrum Pharmaceuticals INC. | $37.29 | 2024-2025 | Rolvedon |
| Eisai INC. | $36.93 | 2025 | |
| Ethicon US, LLC | $36.57 | 2025 | Echelon Circular, Echelon Flex |
| Azurity Pharmaceuticals, INC. | $35.68 | 2025 | Danziten |
| Emd Serono, INC. | $30.14 | 2025 | |
| Medtronic, INC. | $26.72 | 2025 | Signia |
| Astrazeneca Pharmaceuticals LP | $25.67 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.59 | 2025 | Fruzaqla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.64 | 2025 | |
| Tersera Therapeutics LLC | $23.25 | 2025 | Zoladex |
| Karyopharm Therapeutics INC. | $20.26 | 2025 | Xpovio |
| Glaxosmithkline, LLC. | $19.32 | 2025 | Jemperli |
| Sumitomo Pharma America, INC. | $19.03 | 2025 | Orgovyx |
| Smith+Nephew, INC. | $18.73 | 2025 | Grafix Pl, Stravix |
| Rigel Pharmaceuticals, INC. | $18.69 | 2024 | Rezlidhia, Tavalisse |
| Recordati_rare_diseases_inc. | $18.14 | 2025 | Enjaymo |
| Janssen Biotech, INC. | $17.79 | 2025 | Erleada |
| Telix Pharmaceuticals | $17.08 | 2025 | Illuccix |
| Novartis Pharmaceuticals Corporation | $16.30 | 2025 | |
| Beigene USA, INC. | $16.10 | 2024 | Tevimbra |
| Genentech USA, INC. | $15.24 | 2024 | Alecensa, Phesgo, Lunsumio |
| Accord Healthcare, INC. | $15.21 | 2025 | |
| Alnylam Pharmaceuticals INC. | $14.17 | 2025 | Givlaari |
| Beone Medicines USA, INC. | $13.46 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.